Researchers unveiled ErbB-OSV, an engineered vesicular stomatitis virus designed to selectively ablate metastatic ovarian cancer cells by exploiting rewired signaling. The report describes an oncolytic platform built as a targeted VSV variant, with the goal of improving the safety and potency profile compared with a widely used attenuated strain background. In preclinical comparisons, ErbB-OSV showed enhanced anti-tumor activity while maintaining a safety profile characterized as improved relative to VSV-ON-∆M51. The work underscores how virotherapy developers are shifting from broad oncolysis toward circuit-level targeting—engineering the virus to recognize tumor-dependent signaling contexts rather than relying solely on viral tropism.